ReGen Biologics to Conduct Training before AANA Meeting

ReGen's Menaflex(TM) collagen meniscus implant is used in arthroscopic surgery to address the most common form of knee injury, a torn meniscus. The device is inserted to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus.

In the first quarter of 2009, ReGen trained 45 sports medicine surgeons on the Menaflex, who are thought leaders and many of whom are affiliated with professional and university sports teams throughout the United States. The first U.S. commercial surgery using the implant was performed in April. The Menaflex, which has been used for years in Europe, was cleared for U.S. marketing in December 2008.

"U.S. surgeons have shown a high interest in the Menaflex device," said ReGen Chairman and CEO Gerald E. Bisbee Jr., Ph.D. "We are pleased to be conducting training in advance of the AANA annual meeting. The AANA's surgeon members are highly trained arthroscopic specialists who will be among the first to appreciate the potential for treating meniscus injuries with this device."

The surgeon training program provides guidance on insertion and use of the Menaflex device, as well as information concerning the role the device plays in meniscus preservation. The Menaflex procedure has been called an important new treatment option for patients that experience meniscus deficiency, and had been cited for its potential to decrease pain, improve function and decrease reoperation rates.

ReGen will host an exhibit at booth #520-522 throughout the AANA meeting.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's Menaflex(TM) collagen meniscus implant employs proprietary biological collagen scaffold technology to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus of the knee. The Menaflex device has been cleared for sale in Europe and other countries, and is marketed through ReGen's European subsidiary, ReGen Biologics AG. The FDA cleared the Menaflex device for marketing in the United States in December 2008. Visit www.regenbio.com and www.menaflex.com for more information.

About The Arthroscopy Association of North America

Visit www.aana.org for information.

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of ReGen management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2008 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.

SOURCE: ReGen Biologics

ReGen Biologics 
Donna Lucchesi, 480-634-6923 
donna@LBCsuccess.com